858-692-3573 info@denovicontx.com

Pipeline

Denovicon Therapeutics is currently focused on targets in the DNA damage response (DDR) pathways. In particular, we are progressing first-in-class molecules that selectively target PARP1 and PARP2 as therapeutics for a variety of cancers, neurodegenerative conditions, cardiovascular diseases, and viral infections.